Proactive Investors
19 Aug 2026, 12:11 UTC · 9w ago
Impact · against what's priced in
Moderna and Merck receive significant positive catalysts from the successful Phase 3 trial of their personalized mRNA cancer vaccine, which marks a first-of-its-kind clinical validation. Retailers Target and Lowe's see modest price adjustments based on divergent annual outlooks.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Moderna and Merck & Co. reported that their personalized mRNA cancer vaccine, intismeran, combined with Keytruda, met its primary endpoint in a Phase 3 trial for melanoma.
So whatA positive Phase 3 result for a first-of-its-kind personalized cancer vaccine is a major clinical breakthrough with significant valuation implications for the companies involved.
More positive than 99% of claims this week
The US Treasury announced it would at least double its liquidity-support buybacks of longer-dated nominal coupon securities.
So whatDirect government intervention to lower long-term yields reduces borrowing costs and eases systemic pressure on equity valuations.
Continue reading
5 related stories
The successful Phase 3 trial for the personalized cancer vaccine intismeran, which met its primary endpoint of recurrence-free survival, provides a major clinical breakthrough that triggered a 150-176% surge in shares.
Read from the article alone
No priced-in read yet
Merck shares gained over 10% following the positive interim analysis showing that combining their cancer vaccine with Keytruda slowed melanoma recurrence and spread.
Read from the article alone
No priced-in read yet
The stock came under pressure after the company forecast flat comparable sales for the year, signaling a stagnation in discretionary home improvement spending.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 94% of claims this week
President Donald Trump paused 50% tariffs on Canadian goods for three days due to progress toward a potential deal.
More positive than 81% of claims this week
Target raised its annual sales outlook, while Lowe's forecast flat comparable sales for the year.
More positive than 56% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Shares surged significantly following positive Phase 3 trial results for a personalized mRNA cancer vaccine.
More positive than 90% of ticker scores this week
Shares gained over 10% after positive interim results for a cancer vaccine combined with Keytruda.
More negative than 77% of ticker scores this week
Shares came under pressure due to a forecast of flat comparable sales.
More positive than 68% of ticker scores this week
Stock edged higher after the company raised its annual sales outlook.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
+290.4%
Price agrees with the score
$245.81 vs $62.96 close before publication (Aug 18) · not market-adjusted
MRNA chart →−8.9%
Price agrees with the score
$196.55 vs $215.64 close before publication (Aug 18) · not market-adjusted
LOW chart →+10.9%
Price agrees with the score
$149.92 vs $135.17 close before publication (Aug 18) · not market-adjusted
MRK chart →
